These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 7562012)

  • 1. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.
    García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo-Martínez MJ
    J Chemother; 1995 Jun; 7(3):189-96. PubMed ID: 7562012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
    Edlund C; Sabouri S; Nord CE
    Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
    Aldridge KE
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antimicrobial activity of ornidazole and 6 other antibiotics against anaerobic bacteria].
    Alados JC; Martínez-Brocal A; Miranda C; Rojo MD; García V; Domínguez MC; de la Rosa M
    Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):219-22. PubMed ID: 1863621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
    Nord CE
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria.
    Hu J; Zhang J; Wu S; Zhu D; Huang H; Chen Y; Yang Y; Zhang Y
    Int J Antimicrob Agents; 2014 Dec; 44(6):514-9. PubMed ID: 25301712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of Bay Y3118 against anaerobic bacteria.
    Wexler HM; Molitoris E; Finegold SM
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sensitivity of strict anaerobic bacteria to metronidazole, cefoxitin, and clindamycin].
    Dubreuil L; Derriennic M; Reynaud A; Devos J; Romond C; Courtieu A
    Pathol Biol (Paris); 1985 Nov; 33(9):899-903. PubMed ID: 3909082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of anaerobic bacteria to PD 131628.
    Nord CE; Hagelbäck A
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):68-71. PubMed ID: 1314176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of anaerobic bacteria to tosufloxacin.
    Nord CE; Lindmark A; Persson I; Runow C
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):263-5. PubMed ID: 1597207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
    Watt B; Naden M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
    Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
    Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
    Nord CE; Olsson-Liljequist B
    Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
    Schumacher U; Manncke B; Gerbracht K; Werner H
    Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
    Wexler HM; Molitoris E; Reeves D; Finegold SM
    J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of tinidazole against anaerobes in comparison with metronidazole, ornidazole, cefoxitin and lamoxactam].
    Werner H; Kuchenbecker K; Hammann R
    Immun Infekt; 1983 Jun; 11(4):143-7. PubMed ID: 6681175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.